Boltz, PBC
StreetZero Signal 74
About Boltz, PBC
Boltz PBC develops AI models and software for computational drug discovery. Its models predict biomolecular structures, protein-ligand interactions, and estimate binding affinity. Researchers use Boltz Lab and APIs to generate and score candidate molecules and iterate designs in silico. The company was founded in 2025 and incorporated as a public benefit corporation.
LATEST FUNDINGSeed
$97.4M
Announced 2026-10-22
TOTAL RAISED$28M
IN THE NEWS
- 🔗 Boltz - 2026 Company Profile, Funding & Competitors - Tracxn
- 🔗 Boltz Stock | Valuation, Funding, Investors | Notice.co
- 🔗 Boltz - 2026 Funding Rounds & List of Investors - Tracxn
- 🔗 Boltz PBC Launches with $28M to Democratize AI Platforms for Drug Discovery
- 🔗 Boltz launches new platform and agents, announces USD 28M seed round
EMPLOYEES—
FOUNDED2025
HQBoston, MA
Industry
Other Technology
Tags
AIDrug DiscoverySeedBiotech
Investors
Key highlights
- Raised $28M seed round in early 2026 to scale AI platforms for drug discovery.
- Models achieve accurate binding affinity prediction and therapeutic design across modalities.
- Released Boltz Lab platform in beta and first agents for de-novo protein design and hit discovery.
- Emphasizes open-source culture and community building distinct from typical biotech IP practices.
- MIT CSAIL spinout focused on removing compute and infrastructure barriers for scientists.
Ask StreetZero about Boltz, PBC
Put our AI to work on this deal.
Similar companies
Other Other Technology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account